NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations
ND0612, a continuous 24 hours/day subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD), showed superior efficacy compared to oral LD/CD for the...
United States C Warren Olanow Enola Chen Mitsubishi Chemical Group Neuroderm Ltd Mitsubishi Tanabe Pharma America Inc
Source: prnewswire.com